ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2022
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.
Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study.Journal of clinical medicine · 2025Article
- Serum and urine eosinophil-derived neurotoxin (EDN) levels predict biologic response in severe asthma.The World Allergy Organization journal · 2025Article
- Identification of biologic-responsive phenotypes in elderly people with eosinophilic asthma.The journal of allergy and clinical immunology. Global · 2024Article
- Definitions of non-response and response to biological therapy for severe asthma: a systematic review.ERJ open research · 2023Review
- Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.Respiratory research · 2023Article
- Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis.Journal of clinical medicine · 2023Review
- Metabotyping: a tool for identifying subgroups for tailored nutrition advice.The Proceedings of the Nutrition Society · 2023Review
- Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics.ERJ open research · 2023Article
- Comparison between clinical trials and real-world evidence studies on biologics for severe asthma.The Journal of international medical research · 2022Review
- Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma.Biomedicines · 2022Review
- Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Article
- Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study.Journal of asthma and allergy · 2022Article
Corrections and comments
- Commented on by
Authors and funding
21 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundBenralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes.
objectiveTo identify SEA sub-phenotypes with differential responsiveness to benralizumab.
methodsOne hundred and five patients diagnosed with SEA who had completed 6 months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensitization status, blood eosinophil count, IgE levels, FEV
resultsFour clusters were identified: Clusters 2 and 3 included patients with high levels of both IgE and eosinophils (type-2 biomarkers high), whereas Clusters 1 and 4 included patients with only one type-2 biomarker at a high level: IgE in Cluster 1 and eosinophils in Cluster 4. Clusters 2 and 3 (both type-2 biomarkers high) showed the highest response rate to benralizumab in terms of elimination of exacerbations (79% and 80% respectively) compared to Clusters 1 and 4 (52% and 60% respectively). When super-response (the absence of exacerbation without oral corticosteroid use) was assessed, Cluster 2, including patients with more preserved lung function than the other clusters, but comparable exacerbation rate, oral corticosteroid use and symptom severity, was the most responsive cluster (87.5% of patients).
conclusionsOur cluster analysis identified benralizumab differential response sub-phenotypes in SEA, with the potential of improving disease treatment and precision management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.